Key clinical point: A single-fraction high-dose-rate (HDR) brachytherapy boost followed by ultra-hypofractionated stereotactic body radiation therapy (SBRT) to the prostate and/or pelvic lymph nodes shows a low rate of early toxicity in patients with higher-risk prostate cancer.
Major finding: The median follow-up was 24.1 months. No grade 3 or worse genitourinary or gastrointestinal toxicities were reported. Acute and late grade 2 gastrointestinal adverse events (AEs) were 0.99% each. Acute and late grade 2 genitourinary AEs were 5.9% and 9.9%, respectively. The median time to a grade 2 genitourinary toxicity was 6 months.
Study details: A retrospective study of 101 patients with high-risk prostate cancer who received HDR brachytherapy combined with ultra-hypofractionated radiotherapy.
Disclosures: This work was supported by the National Institutes of Health. The authors received research funding, consulting fees, and/or honoraria and/or served as editor-in-chief.
Source: Gorovets D et al. Brachytherapy. 2021 Sep 26. doi: 10.1016/j.brachy.2021.08.006 .